Demyelinating Diseases is an indication for drug development with over 490 pipeline drugs currently active. According to GlobalData, preregistered drugs for Demyelinating Diseases have a 86.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Demyelinating Diseases compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Demyelinating Diseases overview

Demyelinating diseases encompass conditions where the protective myelin sheath surrounding nerve fibers in the central nervous system gets damaged or destroyed. Multiple sclerosis (MS) is a primary example, causing a range of symptoms like fatigue, vision problems, and impaired coordination. Other demyelinating disorders include Guillain-Barré syndrome and leukodystrophies. These diseases disrupt nerve signal transmission, leading to various neurological symptoms. Diagnosis involves imaging, neurological exams, and sometimes spinal fluid analysis. Treatment focuses on managing symptoms, slowing disease progression, and maintaining function through medications, rehabilitation, and lifestyle adjustments. Research seeks to understand these conditions better for improved therapeutic interventions.

For a complete picture of PTSR and LoA scores for drugs in Demyelinating Diseases, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.